Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden

Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden

(2022) Peter Nordström et al.   LANCET

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

(2022) Heba N. Altarawneh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression

(2022) Daniel R Feikin et al.   LANCET

Risk factors for COVID-19 diagnosis, hospitalization, and subsequent all-cause mortality in Sweden: a nationwide study

(2021) Jonathan Bergman et al.   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study

(2021) Christian Holm Hansen et al.   LANCET

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

(2021) Eric J Haas et al.   LANCET

Excess Mortality After COVID-19 in Swedish Long-Term Care Facilities

(2021) Marcel Ballin et al.   Journal of the American Medical Directors Association

Highly effective naturally acquired protection against COVID-19 persists for at least one year: A meta-analysis

(2021) Marek Petráš   Journal of the American Medical Directors Association

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

(2021) Catherine Hyams et al.   LANCET INFECTIOUS DISEASES

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

(2021) Hiam Chemaitelly et al.   NATURE MEDICINE

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

(2021) Jamie Lopez Bernal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase

(2021) Hana M. El Sahly et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months

(2021) Stephen J. Thomas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Prior SARS-CoV-2 Infection With Risk of Breakthrough Infection Following mRNA Vaccination in Qatar

(2021) Laith J. Abu-Raddad et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Protective immunity after recovery from SARS-CoV-2 infection

(2021) Noah Kojima et al.   LANCET INFECTIOUS DISEASES

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

(2021) Ann R. Falsey et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant

(2021) Hiam Chemaitelly et al.   NEW ENGLAND JOURNAL OF MEDICINE

mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern

(2021) Rishi R. Goel et al.   SCIENCE

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

(2021) Jia Wei et al.   Nature Communications

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

(2020) Merryn Voysey et al.   LANCET

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE